142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

Association between treatment of diabetes and breast cancer in 30-79 years old women from metropolitan area of San Juan, Puerto Rico

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Sunday, November 16, 2014

Carola T. Sanchez, BS , Department of Epidemiology and Biostatistics, University of Puerto Rico, Medical Science Campus, Graduate School of Public Health,, San Juan, PR
Cruz M. Nazario, PhD , Department of Biostatistics and Epidemiology, University of Puerto Rico, Graduate School of Public Health, San Juan, PR
Erick L. Suárez, PhD, MS , Department of Biostatistics and Epidemiology, University of Puerto Rico, Graduate School of Public Health, San Juan, PR
Background and Objectives: Breast cancer (BC) and diabetes are two of the most prevalent chronic diseases affecting Puerto Rican women. They both cause a worldwide burden in quality of life and productivity on affected women. Recent studies have been pointing the possible relationship between a frequently used diabetic control drug “metformin®” and BC risk modification. Our aim was to evaluate the relationship between BC and metformin® in 30-79 years old women from San Juan, PR. Methods:Case-control study was conducted using type 2 diabetic women fromthe study Epidemiology of breast cancer in Puerto Rico(Atabey). A telephone interview was performed to assess exposure to metformin®. BC risk factors variables were obtain from Atabey database. Logistic regression analysis was performed to determine factors associated with BC risk.Results: Significant difference by BC diagnosis was observed for the use of hormone replacement therapy (P=0.07).Results from the unadjusted logistic regression analysis suggeststhe possibility of been diagnosed with BC in women who didn’t use “metformin®”is 6.0% (POR: 1.06, 95% CI: 0.18-5.97) the possibility in women that were using “metformin®”. When stratified by age we found adecrease riskin women older than 64y/o using metformin® (OR: 0.83, IC95%:0.071- 10.34).Conclusions:Our study suggests that metformin® is protective for BC in women older than 64 y/o. The magnitude of the association and the lack of statistical significance may be explained by our greatest limitation, the small sample size. Future studies to further assess the association between metformin® and BC are needed. Aknowledgments: The content is solely the responsibility of the authors.

Learning Areas:

Basic medical science applied in public health
Chronic disease management and prevention
Diversity and culture
Implementation of health education strategies, interventions and programs
Public health or related education

Learning Objectives:
Evaluate the relationship between breast cancer and diabetic control drug “metformin®”in 30-79 years old women from San Juan, PR.

Keyword(s): Cancer and Women’s Health, Diabetes

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: This is the abstract of the poster of my thesis dissertation. I have been working of this project for two years. I have been working with cancer and insulin related diseases and among my interests has been the development of epidemiological research related to women health, chronic diseases and population health disparities.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.